Dr. Reddy's Laboratories Ltd. (
recently announced the launch of its therapeutic equivalent
generic version of Depakote ER.
Depakote ER is approved for the treatment of acute manic
episodes associated with bipolar disorder and the prevention of
migraine headaches. Depakote ER can be used alone or with other
medicines to treat complex partial seizures in patients (≥10
years of age) and simple and complex absence seizures, with or
without other seizure types.
According to IMS Health, Depakote ER and its generic versions
generated U.S. revenues of approximately $194 million MAT (moving
annual total) in the 12 months ending Jun 2013.
Revenues at Dr. Reddy's Global Generics segment were up 15% to
$368 million in the first quarter ended Jun 30, 2013. Strong
sales in North America and emerging markets led to the growth at
the Global Generics division. Generics revenues increased in
North America (up 37%), Russia and other CIS (Commonwealth of
Independent States) markets (up 8%), and the rest of the world,
or RoW (up 12%).
During the first quarter of fiscal 2014, Dr. Reddy's filed 2
abbreviated new drug applications (ANDAs) with the U.S. Food and
Drug Administration (FDA). As of Jul 30, 2013, Dr. Reddy's has 64
ANDAs pending approval with the FDA, of which 38 are Para IV
filings and 8 are first-to-file.
Dr. Reddy's carries a Zacks Rank #4 (Sell). Currently,
looks more attractive with a Zacks Rank #2 (Buy). Other companies
Questcor Pharmaceuticals Inc.
) look better positioned with a Zacks Rank #1 (Strong Buy).
ACTAVIS INC (ACT): Free Stock Analysis Report
ACTELION LTD (ALIOF): Get Free Report
QUESTCOR PHARMA (QCOR): Free Stock Analysis
DOCTOR REDDYS (RDY): Free Stock Analysis
To read this article on Zacks.com click here.